HDAC6-selective inhibitors C1A and ACY-1215 were potent in multiple myeloma cell lines (ARH77, JJN3, KMS12, U266, RPMI8226, KMS11, OPM-2) with a mean GI50 of 0.48 and 1.04, respectively (Supplementary Table 1). Here, HDAC6 is linked to plasma cell myeloma.